The study focuses on people who have experienced a myocardial infarction, commonly known as a heart attack. After a heart attack, doctors often prescribe two blood‑thinning medicines to reduce the risk of another clot; this approach is called Dual Anti Platelet Therapy. In this trial, participants receive either the blood‑thinner ticagrelor by itself or the same medicine together with a low dose of acetylsalicylic acid (often called aspirin). To keep the comparison fair, a matching placebo tablet is used in place of aspirin for those who do not take it.
The purpose of the study is to determine whether taking ticagrelor alone is as safe and effective as the standard two‑medicine regimen in preventing serious bleeding and major heart problems over one year. Participants are randomly assigned to one of the two groups and take the assigned tablets daily for twelve months, with routine check‑ups scheduled throughout the year to monitor health and any side effects.
Researchers will look at two main outcomes: first, any bleeding events classified by the Bleeding Academic Research Consortium as type 2, 3, or 5, which represent moderate to severe bleeding; and second, a combined measure that includes death from any cause, another heart attack, stroke, or the need for a procedure to open blocked heart arteries (coronary revascularization). Information on these events will be collected during the scheduled visits and recorded for analysis.
France 
